MedWatch

Analyst "positively surprised" by Demant's Q1 development

The hearing aid manufacturer recently publicized its 2022 Q1 report, and a Jyske Bank analyst now expects that Demant’s growth momentum will carry through the second quarter.

Photo: Dado Ruvic/REUTERS / X02714

Jyske Bank has a positive view of Demant’s first quarter developments, which were announced by the hearing aid manufacturer on Tuesday.

Consequently, the Danish bank has raised its share price target for the firm to DKK 360 from DKK 340 (USD 50.8 from USD 48.1), maintaining its ”buy” recommendation.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs